ArticleJournal of cancer research and clinical oncology2025
Depletion of UBAP2L suppresses colorectal cancer cell proliferation and radiotherapy resistance by regulating GPX4.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to investigate the potential role of UBAP2L in the proliferation and radiotherapy resistance of colorectal (CRC) cells.
methodsClinical and pathological data were collected from 257 patients with stage I-III primary CRC who underwent surgical treatment at the Affiliated Hospital of Qingdao University (Qingdao, China) and Shandong Electric Power Central Hospital (Shandong China) from 2015 to 2019. Additionally, tumor biopsy specimens were collected from 30 patients with locally advanced rectal cancer. The expression of UBAP2L in CRC tissues was tested using immunochemistry. The association of UBAP2L expression with clinicopathological data and outcomes of patients with CRC was determined. Overexpression and knockdown cells were constructed to evaluate the proliferation and radiotherapy resistance of UBAP2L in CRC cells.
resultsOur results showed UBAP2L was significantly overexpressed in CRC tissues compared to adjacent non-tumor tissues (75.48% vs. 21.01%, P < 0.05). UBAP2L expression is associated with tumor location (P = 0.001), and deeper tumor invasion (T stage, P = 0.001). Survival analysis showed that the disease-free survival of patients with high UBAP2L expression was significantly shorter than that of patients with low UBAP2L expression (P = 0.006). Gain and loss-of-function experiments demonstrated UBAP2L-KD significantly inhibited the proliferation and radio-resistance of CRC cells, while UBAP2L-OE promoted the proliferation and radio-resistance of CRC cells. Moreover, ferrostatin-1 reversed the inhibitory effect of UBAP2L-KD on CRC cell proliferation and radio-resistance, while RSL3 reversed the promoting effect of UBAP2L-OE on CRC cell proliferation and radio-resistance. These findings suggest that UBAP2L regulates CRC cell proliferation and radio-resistance in a GPX4-dependent manner.
conclusionUBAP2L is highly expressed in CRC, and its expression correlates with poor disease-free survival. Depletion of UBAP2L inhibits CRC proliferation and radio-resistance by downregulating GPX4. Therefore, UBAP2L may be a promising therapeutic target for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.